Cargando…

Polyvalent Bacterial Lysate Protects Against Pneumonia Independently of Neutrophils, IL-17A or Caspase-1 Activation

Polyvalent bacterial lysates have been in use for decades for prevention and treatment of respiratory infections with reported clinical benefits. However, besides claims of broad immune activation, the mode of action is still a matter of debate. The lysates, formulated with the main bacterial specie...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrara, Florencia, Rial, Analía, Suárez, Norma, Chabalgoity, José Alejandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108696/
https://www.ncbi.nlm.nih.gov/pubmed/33981296
http://dx.doi.org/10.3389/fimmu.2021.562244
_version_ 1783690167262904320
author Ferrara, Florencia
Rial, Analía
Suárez, Norma
Chabalgoity, José Alejandro
author_facet Ferrara, Florencia
Rial, Analía
Suárez, Norma
Chabalgoity, José Alejandro
author_sort Ferrara, Florencia
collection PubMed
description Polyvalent bacterial lysates have been in use for decades for prevention and treatment of respiratory infections with reported clinical benefits. However, besides claims of broad immune activation, the mode of action is still a matter of debate. The lysates, formulated with the main bacterial species involved in respiratory infections, are commonly prepared by chemical or mechanical disruption of bacterial cells, what is believed influences the biological activity of the product. Here, we prepared two polyvalent lysates with the same composition but different method of bacterial cell disruption and evaluated their biological activity in a comparative fashion. We found that both bacterial lysates induce NF-kB activation in a MyD88 dependent manner, suggesting they work as TLR agonists. Further, we found that a single intranasal dose of any of the two lysates, is sufficient to protect against pneumococcal pneumonia, suggesting that they exert similar biological activity. We have previously shown that protection against pneumococcal pneumonia can also be induced by prior S. pneumoniae sub lethal infection or therapeutic treatment with a TLR5 agonist. Protection in those cases depends on neutrophil recruitment to the lungs, and can be associated with increased local expression of IL-17A. Here, we show that bacterial lysates exert protection against pneumococcal pneumonia independently of neutrophils, IL-17A or Caspase-1/11 activation, suggesting the existence of redundant mechanisms of protection. Trypsin-treated lysates afford protection to the same extent, suggesting that just small peptides suffice to exert the protective effect or that the molecules responsible for the protective effect are not proteins. Understanding the mechanism of action of bacterial lysates and deciphering the active components shall allow redesigning them with more precisely defined formulations and expanding their range of action.
format Online
Article
Text
id pubmed-8108696
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81086962021-05-11 Polyvalent Bacterial Lysate Protects Against Pneumonia Independently of Neutrophils, IL-17A or Caspase-1 Activation Ferrara, Florencia Rial, Analía Suárez, Norma Chabalgoity, José Alejandro Front Immunol Immunology Polyvalent bacterial lysates have been in use for decades for prevention and treatment of respiratory infections with reported clinical benefits. However, besides claims of broad immune activation, the mode of action is still a matter of debate. The lysates, formulated with the main bacterial species involved in respiratory infections, are commonly prepared by chemical or mechanical disruption of bacterial cells, what is believed influences the biological activity of the product. Here, we prepared two polyvalent lysates with the same composition but different method of bacterial cell disruption and evaluated their biological activity in a comparative fashion. We found that both bacterial lysates induce NF-kB activation in a MyD88 dependent manner, suggesting they work as TLR agonists. Further, we found that a single intranasal dose of any of the two lysates, is sufficient to protect against pneumococcal pneumonia, suggesting that they exert similar biological activity. We have previously shown that protection against pneumococcal pneumonia can also be induced by prior S. pneumoniae sub lethal infection or therapeutic treatment with a TLR5 agonist. Protection in those cases depends on neutrophil recruitment to the lungs, and can be associated with increased local expression of IL-17A. Here, we show that bacterial lysates exert protection against pneumococcal pneumonia independently of neutrophils, IL-17A or Caspase-1/11 activation, suggesting the existence of redundant mechanisms of protection. Trypsin-treated lysates afford protection to the same extent, suggesting that just small peptides suffice to exert the protective effect or that the molecules responsible for the protective effect are not proteins. Understanding the mechanism of action of bacterial lysates and deciphering the active components shall allow redesigning them with more precisely defined formulations and expanding their range of action. Frontiers Media S.A. 2021-04-26 /pmc/articles/PMC8108696/ /pubmed/33981296 http://dx.doi.org/10.3389/fimmu.2021.562244 Text en Copyright © 2021 Ferrara, Rial, Suárez and Chabalgoity https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Ferrara, Florencia
Rial, Analía
Suárez, Norma
Chabalgoity, José Alejandro
Polyvalent Bacterial Lysate Protects Against Pneumonia Independently of Neutrophils, IL-17A or Caspase-1 Activation
title Polyvalent Bacterial Lysate Protects Against Pneumonia Independently of Neutrophils, IL-17A or Caspase-1 Activation
title_full Polyvalent Bacterial Lysate Protects Against Pneumonia Independently of Neutrophils, IL-17A or Caspase-1 Activation
title_fullStr Polyvalent Bacterial Lysate Protects Against Pneumonia Independently of Neutrophils, IL-17A or Caspase-1 Activation
title_full_unstemmed Polyvalent Bacterial Lysate Protects Against Pneumonia Independently of Neutrophils, IL-17A or Caspase-1 Activation
title_short Polyvalent Bacterial Lysate Protects Against Pneumonia Independently of Neutrophils, IL-17A or Caspase-1 Activation
title_sort polyvalent bacterial lysate protects against pneumonia independently of neutrophils, il-17a or caspase-1 activation
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108696/
https://www.ncbi.nlm.nih.gov/pubmed/33981296
http://dx.doi.org/10.3389/fimmu.2021.562244
work_keys_str_mv AT ferraraflorencia polyvalentbacteriallysateprotectsagainstpneumoniaindependentlyofneutrophilsil17aorcaspase1activation
AT rialanalia polyvalentbacteriallysateprotectsagainstpneumoniaindependentlyofneutrophilsil17aorcaspase1activation
AT suareznorma polyvalentbacteriallysateprotectsagainstpneumoniaindependentlyofneutrophilsil17aorcaspase1activation
AT chabalgoityjosealejandro polyvalentbacteriallysateprotectsagainstpneumoniaindependentlyofneutrophilsil17aorcaspase1activation